OncoC4 Begins Phase 1/2 Clinical Trial for Alzheimer's Treatment with ONC-841
OncoC4 Inc., a biopharmaceutical company based in Rockville, Maryland, has announced the dosing of the first participant in its Phase 1/2 clinical trial for ONC-841, an investigational therapy for Alzheimer's disease. The trial follows the clearance of the Investigational New Drug application by the National Medical Product Administration. ONC-841 is the first clinical stage anti-SIGLEC 10 antibody, initially developed for solid tumors. The trial aims to test the safety and clinical activity of ONC-841 in treating Alzheimer's, leveraging safety data from previous oncology studies. 
